In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: March 2009

Executive Summary

Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries. March 2009 dealmaking highlights: BMS' worldwide ex-Japanese license to Nissan/Teijin's CV candidate NTC801 topped the alliance list in terms of potential deal value at $210mm. The remaining pharma alliances for March didn't even surpass $50mm in pre-commercial value. In M&As, the Big Pharma mega merger of Merck and Schering-Plough was the biggest news, in a deal valued around $42bn. Pharmaceutical financings were down by about $100mm compared with February, and Early VC rounds made up the majority of the $406mm raised. Funding for device firms, on the other hand, was up from last month to $297mm thanks to a strong showing of late venture financings.

You may also be interested in...



Start-Up Scanwell Adds Another Collaboration, Targets Home COVID-19 Testing With BD

Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.  

Execs On The Move: Slew Of Directorships At Zimmer And 908 Devices

908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.

Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis

The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel